Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pacritinib in Renal Impairment
NCT02807077Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pacritinib in myelofibrosis (MF) (5 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started Nov 2014; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02807077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807077.